Pelthos Therapeutics Inc. (PTHS) stock
PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.38−0.61 (-8.73%)
Close on Nov 20, 2026Market cap $24.43MP/E –Yield –
Pelthos Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
For fiscal 2025 it was -$22.69M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$22.69M | – |
| FY2024 | Dec 31, 2024 | -$5.79M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$7.67M | – |
| Q1 FY2026 | Mar 31, 2026 | -$13.32M | – |
| Q2 FY2025 | Jun 30, 2025 | -$447.00K | – |
| Q1 FY2025 | Mar 31, 2025 | -$632.00K | – |
See a number that looks wrong?